Sinovac Biotech ( (SVA) ) just unveiled an update.
On April 15, 2025, Sinovac Biotech Ltd. announced that Grant Thornton Zhitong Certified Public Accountants LLP resigned as its independent registered public accounting firm. The resignation was not due to disagreements with the company’s management or board. However, Grant Thornton stated that its previous audit opinions on Sinovac’s financial statements and internal controls for the years ending December 31, 2023, 2022, and 2021 should no longer be relied upon. This decision followed a Privy Council ruling that questioned the legitimacy of the company’s board since 2018, leading to uncertainties about past corporate actions. Consequently, Sinovac’s audited financial statements for 2024 will be delayed, and the company is in the process of engaging a new accounting firm.
Spark’s Take on SVA Stock
According to Spark, TipRanks’ AI Analyst, SVA is a Neutral.
Sinovac Biotech’s overall score reflects its strong liquidity and balance sheet, offset by poor financial performance and lack of earnings. The technical indicators suggest neutrality, and the valuation appears unattractive due to the negative P/E ratio.
To see Spark’s full report on SVA stock, click here.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a biotechnology company based in Beijing, China, primarily engaged in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company focuses on providing vaccines for diseases such as hepatitis, influenza, and COVID-19, serving both domestic and international markets.
Average Trading Volume: 8,227
Technical Sentiment Signal: Hold
Current Market Cap: $460.3M
See more insights into SVA stock on TipRanks’ Stock Analysis page.